[HTML][HTML] Effect of dialysis dose and membrane flux in maintenance hemodialysis

G Eknoyan, GJ Beck, AK Cheung… - … England Journal of …, 2002 - Mass Medical Soc
Background The effects of the dose of dialysis and the level of flux of the dialyzer membrane
on mortality and morbidity among patients undergoing maintenance hemodialysis are …

[HTML][HTML] Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients

AK Cheung, MJ Sarnak, G Yan, JT Dwyer, RJ Heyka… - Kidney international, 2000 - Elsevier
Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Background
Cardiovascular diseases are the most common causes of death among chronic hemodialysis …

Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial

…, AP Auchus, RN Bryan, G Chelune, AK Cheung… - Jama, 2019 - jamanetwork.com
Importance There are currently no proven treatments to reduce the risk of mild cognitive
impairment and dementia. Objective To evaluate the effect of intensive blood pressure control on …

[HTML][HTML] Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study

AK Cheung, MJ Sarnak, G Yan, M Berkoben… - Kidney international, 2004 - Elsevier
… Author links open overlay panel Alfred K. Cheung , Mark J. Sarnak , Guofen Yan , Michael
Berkoben , Robert Heyka , Allen Kaufman , Julia Lewis , Michael Rocco , Robert Toto , David …

Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint

…, VP Sukhatme, AK Cheung - Journal of the American …, 2006 - journals.lww.com
Hemodialysis vascular access dysfunction is a major cause of morbidity and hospitalization
in the hemodialysis population. The major cause of hemodialysis vascular access …

Serum β-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study

AK Cheung, MV Rocco, G Yan… - Journal of the …, 2006 - journals.lww.com
In the randomized Hemodialysis (HEMO) Study, chronic high-flux dialysis, as defined by higher
β-2 microglobulin (β 2 M) clearance, compared with low-flux dialysis did not significantly …

FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis

J Kendrick, AK Cheung, JS Kaufman… - Journal of the …, 2011 - journals.lww.com
Concentrations of the phosphate-regulating hormone fibroblast growth factor-23 (FGF-23)
are elevated in patients with chronic kidney disease (CKD), but whether higher plasma FGF-…

GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

…, K Willis, E Lewis, D De Zeeuw, AK Cheung… - American Journal of …, 2014 - Elsevier
… , PhD (FDA), Edmund Lewis, MD, Dick de Zeeuw, MD, PhD, and Alfred K. Cheung, MD. The
analytical group was chaired by Josef Coresh, MD, PhD, and comprised the observational …

The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial …

…, KM Sink, CG Foy, DR Berlowitz, AK Cheung… - Clinical …, 2014 - journals.sagepub.com
Background: High blood pressure is an important public health concern because it is highly
prevalent and a risk factor for adverse health outcomes, including coronary heart disease, …

Lipoprotein metabolism and lipid management in chronic kidney disease

…, F Kronenberg, S Beddhu, AK Cheung - Journal of the …, 2007 - journals.lww.com
Dyslipidemia is an established cardiovascular (CV) risk factor in the general population. In
chronic kidney disease (CKD), however, epidemiologic studies (1–3) and clinical trials (4–12) …